Actuate Therapeutics, Inc. Common stock (ACTU)Healthcare | Biotechnology | Fort Worth, United States | NasdaqGM
1.66 USD
-0.04
(-2.071%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.63 -0.02 (-0.025%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:33 a.m. EDT
The immediate outlook is clouded by severe technical weakness; the stock has collapsed from its 52-week high of $9.22 to trade near $1.27, currently sitting well below both its 50-day and 200-day moving averages. While the company recently secured capital via a public offering and reported promising clinical data showing doubled one-year survival rates in pancreatic cancer trials, these fundamental positives have failed to arrest the bleeding price action. The statistical forecasting model offers zero directional guidance with very low confidence, reflecting the high volatility and lack of clear trend in the recent price history. Consequently, the short-term setup remains bearish due to the disconnect between the positive news cycle and the relentless downward price pressure. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.273053 |
| AutoETS | 0.423233 |
| AutoARIMA | 0.424232 |
| MSTL | 0.436903 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 1.67 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.001 |
| Excess Kurtosis | 1.02 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 39,743,504 |
| Forward P/E | -2.28 |
| Beta | 0.78 |
| Website | https://actuatetherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.80574715 |
| Address1 | 1,751 River Run |
| Address2 | Suite 400 |
| All Time High | 11.99 |
| All Time Low | 0.9 |
| Ask | 1.45 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 637,360 |
| Average Daily Volume3 Month | 347,550 |
| Average Volume | 347,550 |
| Average Volume10Days | 637,360 |
| Beta | 0.783 |
| Bid | 0.7992 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 0.041 |
| City | Fort Worth |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.655 |
| Current Ratio | 1.248 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.7799 |
| Day Low | 1.6301 |
| Display Name | Actuate Therapeutics |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 35,317,664 |
| Eps Current Year | -0.665 |
| Eps Forward | -0.725 |
| Eps Trailing Twelve Months | -0.85 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.3799 |
| Fifty Day Average Change | 0.2751 |
| Fifty Day Average Change Percent | 0.19936226 |
| Fifty Two Week Change Percent | -80.574715 |
| Fifty Two Week High | 9.22 |
| Fifty Two Week High Change | -7.5650005 |
| Fifty Two Week High Change Percent | -0.82049894 |
| Fifty Two Week Low | 0.9 |
| Fifty Two Week Low Change | 0.755 |
| Fifty Two Week Low Change Percent | 0.8388889 |
| Fifty Two Week Range | 0.9 - 9.22 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,723,555,800,000 |
| Float Shares | 8,604,048 |
| Forward Eps | -0.725 |
| Forward P E | -2.2827585 |
| Free Cashflow | -12,478,303 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 12 |
| Fullday Change | -0.0350001 |
| Fullday Change Percent | -2.07101 |
| Fullday Price | 1.63 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15411 |
| Held Percent Institutions | 0.55986 |
| Implied Shares Outstanding | 24,014,202 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-08-13 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas. |
| Long Name | Actuate Therapeutics, Inc. Common stock |
| Market | us_market |
| Market Cap | 39,743,504 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_313171219 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -20,453,808 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 40,584,001 |
| Number Of Analyst Opinions | 4 |
| Open | 1.69 |
| Operating Cashflow | -19,836,202 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 817 887 8455 |
| Post Market Change | -0.024999976 |
| Post Market Change Percent | -1.5105726 |
| Post Market Price | 1.63 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 1.69 |
| Price Eps Current Year | -2.4887216 |
| Price Hint | 4 |
| Price To Book | 40.365852 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.163 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0350001 |
| Regular Market Change Percent | -2.07101 |
| Regular Market Day High | 1.7799 |
| Regular Market Day Low | 1.6301 |
| Regular Market Day Range | 1.6301 - 1.7799 |
| Regular Market Open | 1.69 |
| Regular Market Previous Close | 1.69 |
| Regular Market Price | 1.655 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 231,266 |
| Return On Assets | -2.13398 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 24,014,202 |
| Shares Percent Shares Out | 0.029000001 |
| Shares Short | 695,971 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 754,754 |
| Short Name | Actuate Therapeutics, Inc. |
| Short Percent Of Float | 0.0659 |
| Short Ratio | 2.43 |
| Source Interval | 15 |
| State | TX |
| Symbol | ACTU |
| Target High Price | 15.05 |
| Target Low Price | 5.0 |
| Target Mean Price | 10.0125 |
| Target Median Price | 10.0 |
| Total Cash | 4,425,841 |
| Total Cash Per Share | 0.184 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.4465 |
| Two Hundred Day Average Change | -1.7915001 |
| Two Hundred Day Average Change Percent | -0.5198027 |
| Type Disp | Equity |
| Volume | 231,266 |
| Website | https://actuatetherapeutics.com |
| Zip | 76,107 |